SCHEMBL11224969

SCHEMBL11224969

CCOC(=O)Cc1cccc(N)c1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.50
ALDH1A1 P00352 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PKM P14618 1/20 0.46
NLRP3 Q96P20 2/20 0.43
CYP4F2 P78329 2/20 0.43
CYP4A11 Q02928 2/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
TBXAS1 P24557 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
EGFR P00533 2/20 0.40
MMP2 P08253 1/20 0.40
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28137286 0.85 CHEK1 (0.51) CHEK1ALDH1A1HSD17B10PKMNLRP3
SCHEMBL3142760 0.85 ALDH1A1 (0.54) CHEK1ALDH1A1HSD17B10PKMNLRP3
SCHEMBL11214621 0.84 CYP4F2 (0.59) CHEK1ALDH1A1HSD17B10NLRP3CYP4F2
SCHEMBL28118721 0.84 CHEK1 (0.50) CHEK1ALDH1A1HSD17B10PKMNLRP3
SCHEMBL29749375 0.83 ALDH1A1 (0.49) ALDH1A1HSD17B10CYP4F2CYP4A11GABRA1
SCHEMBL21438124 0.83 PKM (0.51) ALDH1A1HSD17B10PKMNLRP3CYP4F2
SCHEMBL10268521 0.83 ALDH1A1 (0.49) ALDH1A1HSD17B10CYP4F2CYP4A11GABRA1
SCHEMBL29853174 0.83 PKM (0.51) ALDH1A1HSD17B10PKMNLRP3CYP4F2
SCHEMBL7563081 0.83 CHEK1 (0.49) CHEK1ALDH1A1HSD17B10PKMNLRP3
SCHEMBL27501902 0.82 CYP4F2 (0.56) CHEK1ALDH1A1HSD17B10CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118176187-A Condensed ring compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-06-11 CN disclosed
WO-2023066357-A1 FUSED CYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2023-04-27 WO disclosed
US-8785474-B2 Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions GRUENENTHAL GMBH (DE) 2014-07-22 US disclosed
US-8084484-B2 Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions GRUENENTHAL GMBH (DE) 2011-12-27 US disclosed
US-8084484-B2 Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions GRUENENTHAL GMBH (DE) 2011-12-27 US disclosed
US-20110301156-A1 Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions GRUENENTHAL GMBH (DE) 2011-12-08 US disclosed
US-20090156590-A1 Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions GRUENENTHAL GMBH (DE) 2009-06-18 US disclosed
US-20090156590-A1 Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions GRUENENTHAL GMBH (DE) 2009-06-18 US disclosed
EP-0081321-A1 2-Aminophenol derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1983-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156590-A1 Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions TRPV1, OPRL1, TRPV2 CHEK1 4726/4885ALDH1A1 1590/4885HSD17B10 2199/4885
US-20110301156-A1 Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions TRPV1, OPRL1, TRPV2 CHEK1 4753/4885ALDH1A1 1566/4885HSD17B10 2088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.